Powering Results In Upstream mAb Process Scale Up

Upstream monoclonal antibody production can be limited by lengthy seed trains, manual handling, and insufficient vessel capacity rather than bioreactor size alone. Process intensification addresses these constraints by increasing inoculation density, shortening seed duration, and moving cultures into production faster. When seed and production strategies are combined, economic modeling indicates the potential for up to a 163% increase in titer, an approximately 20% reduction in upstream footprint, and an approximately 50% reduction in cost per gram. Integrated technologies from Thermo Fisher Scientific support this approach through high-density cell banking, optimized cell culture systems, scalable single-use bioreactors, closed fluid handling, and process analytics.

Explore how these capabilities can reduce processing steps and manufacturing complexity while expanding mAb output within an existing facility footprint.